Global Ketorolac Tromethamine Market Size By Type (Injection, Ophthalmic), By Application (Short-term treatment of pain, Ophthalmic Surgery), By Region, And Segment Forecasts, 2023 to 2032

The Global Ketorolac Tromethamine Market was valued at USD 420 million in 2023 and is projected to reach USD 675 million by 2031, expanding at a CAGR of 6.1% during the forecast period (2023–2031). This growth is fueled by the increasing use of ketorolac tromethamine in post-operative pain management, the rising prevalence of chronic conditions such as arthritis and musculoskeletal disorders, and the growing demand for non-opioid analgesics amid the global opioid crisis. Ketorolac, a potent NSAID, offers short-term pain relief and is widely administered in both hospital and ambulatory settings, bolstering its adoption across the healthcare sector.

Drivers:

1. Surge in Postoperative Procedures:

With the rising number of surgeries globally—orthopedic, dental, and abdominal—ketorolac tromethamine's role as a first-line non-opioid analgesic is gaining traction.

2. Preference for Non-Opioid Analgesics:

The growing awareness of opioid addiction and associated side effects is shifting prescribing trends toward safer alternatives like ketorolac, especially in pain management guidelines.

3. Increasing Geriatric Population:

As aging populations are more prone to inflammatory and musculoskeletal conditions, the demand for anti-inflammatory medications like ketorolac continues to grow.

Restraints:

1. Adverse Side Effects and FDA Warnings:

Ketorolac is known for potential side effects including gastrointestinal bleeding and renal complications, limiting its long-term use and application.

2. Strict Regulatory Control:

Due to its potent nature and side effects, ketorolac use is often limited to short durations and monitored strictly, which can hinder broader adoption.

Opportunity:

1. Expansion in Emerging Economies:

Rising healthcare infrastructure, increasing accessibility to surgical procedures, and supportive government initiatives in Asia-Pacific and Latin America present lucrative growth opportunities.

2. Product Innovations and Combinations:

Development of novel drug delivery systems (e.g., intranasal sprays, ophthalmic solutions) and ketorolac in combination therapies is expected to fuel market innovation.

Market by System Type Insights:

By formulation, the Injectable Ketorolac segment held the largest share in 2023. Its rapid onset and efficacy in acute pain settings make it the preferred choice in hospitals and surgical centers. However, the Ophthalmic Ketorolac segment is poised for notable growth, especially in treating post-operative eye inflammation and seasonal allergic conjunctivitis, driven by increasing eye procedures and advancements in ophthalmology.

Market by End-Use Insights:

The Hospitals segment emerged as the leading end-use category, accounting for over 50% of the market revenue in 2023. The use of injectable ketorolac in inpatient post-surgical pain management underpins this dominance. Meanwhile, the Retail Pharmacies segment is expected to expand steadily, driven by the rising demand for ketorolac tablets and eye drops for outpatient care.

Market by Regional Insights:

North America led the global ketorolac tromethamine market in 2023 due to robust healthcare systems, high surgical volumes, and favorable reimbursement structures. Asia-Pacific, on the other hand, is projected to record the fastest growth, attributed to rising disposable incomes, increasing healthcare awareness, and expanding pharmaceutical markets in India, China, and Southeast Asia.

Competitive Scenario:

Major players in the Ketorolac Tromethamine Market include Pfizer Inc., Mylan N.V., Apotex Inc., Sandoz (Novartis AG), Teva Pharmaceuticals, Sun Pharmaceutical Industries Ltd., Fresenius Kabi, Hikma Pharmaceuticals, and Cipla Ltd. These companies are engaged in expanding their generic portfolios, investing in biosimilar innovations, and strengthening distribution networks through strategic collaborations.

Scope of Work – Global Ketorolac Tromethamine Market

Key Market Developments:

2023: Pfizer expanded its manufacturing capacity in North America to enhance the production of injectable pain management drugs, including ketorolac tromethamine.

2024: Sandoz launched a new ophthalmic ketorolac formulation targeting post-cataract inflammation in Europe.

2025: Mylan collaborated with a regional distributor in Southeast Asia to expand market access for its oral ketorolac products in emerging economies.

FAQs:

1) What is the current market size of the Global Ketorolac Tromethamine Market?

The market was valued at USD 420 million in 2023.

2) What is the major growth driver of the Global Ketorolac Tromethamine Market?

The primary driver is the increasing preference for non-opioid analgesics in post-operative pain management.

3) Which is the largest region during the forecast period in the Global Ketorolac Tromethamine Market?

North America is the largest region, while Asia-Pacific is the fastest-growing.

4) Which segment accounted for the largest market share in the Global Ketorolac Tromethamine Market?

The Injectable Ketorolac segment held the largest share in 2023.

5) Who are the key market players in the Global Ketorolac Tromethamine Market?

Key players include Pfizer, Mylan, Apotex, Sandoz, Teva, Sun Pharma, and Fresenius Kabi.